Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
about
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.Consistency Test between Scoring Systems for Predicting Outcomes of Chronic Myeloid Leukemia in a Saudi Population Treated with Imatinib.Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemiaThe impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.Current trends in molecular diagnostics of chronic myeloid leukemia.Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.Prognostic discrimination based on the EUTOS long term survival score within the international registry for chronic myeloid leukemia in children and adolescents.Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.Chronic myeloid leukemia: room for improvement?Innovation in hematology. Perspectives: CML 2016Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis.Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey.
P2860
Q36302377-3F698329-7A05-40F4-AB83-D85F70770C23Q37027098-F8AC17D9-B1B3-44D2-AD08-0A0008AC44D4Q37668884-A6175E32-CD2A-4E33-AB89-B86C9B2A1297Q37744812-225D13D0-FFFE-49FF-89A2-E8CA815DA819Q38403647-8C40FC33-8584-4C96-A7F9-D38570565C30Q38620872-219847AE-F974-4ADD-A92A-C92BD8A5FC6EQ38725366-E5C1BE47-F4E6-47CD-A08C-AB3F49A31585Q38787015-48BE36B7-8F04-4BCB-9C93-56A960249BA3Q38963992-36D7A5D1-960D-431E-B3C5-21947E4CDA8AQ39259447-C5AE9761-8C34-4FDC-B20C-A2F74F8EAEA0Q39446340-91294216-21FD-4E9A-863B-6EBC7E0472D9Q39457369-76237F46-69F2-4A75-AC2B-616D7A74BAB1Q40062215-C77D6BAF-29D1-4293-B766-F872BC8B7E93Q40071286-A2A1CAE4-1E36-467A-90AA-B8A7A1921840Q40302552-763E6F19-3F26-4C47-9539-40F05CD2FB6AQ40382581-C7844A3F-9966-4787-8ACE-0942B8174290Q40607863-BE03CB1B-8B2F-4611-AC12-35D63DD9A670Q42348447-9E51EE99-F00C-4A36-B4E9-2FE41642B0BEQ42397473-82314CCC-BE84-4269-A600-4D5F1B9FFDD2Q45304786-9668F56B-A793-45B5-BDF7-2567416123FBQ47096076-427548D1-300D-419C-B47D-55F325B3E6E7Q47113340-880315F1-37C9-4E87-8351-BFB6BB36D3FCQ47162677-9E4C4114-DD65-4A74-BEF1-88240DC52312Q47413364-C6DD1649-63F6-4F9E-8705-CD16D72710B7Q47824125-3AF144B2-9BCB-4B33-9D31-330C2F3B3EDCQ47917650-F9BE415C-B8C6-4447-A57F-4BA7E859F0F9Q48306359-AE05B34F-4CA7-4409-9AC1-1842901D76A7Q48778777-174428CE-4006-4969-A839-B4FB36154082Q50421953-ECA4332C-E85A-4C7A-AA78-0372E51B29C3Q50997822-38FED46D-B144-42CD-8047-2823C0A81407Q55345383-D7B061E6-B6CF-4975-9F5D-F2C000A246D8
P2860
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Prognosis of long-term surviva ...... with chronic myeloid leukemia.
@en
type
label
Prognosis of long-term surviva ...... with chronic myeloid leukemia.
@en
prefLabel
Prognosis of long-term surviva ...... with chronic myeloid leukemia.
@en
P2093
P2860
P356
P1433
P1476
Prognosis of long-term surviva ...... with chronic myeloid leukemia.
@en
P2093
B Simonsson
F Castagnetti
F Cervantes
G Ossenkoppele
M Baccarani
M Pfirrmann
R Hehlmann
S Saussele
P2860
P2888
P356
10.1038/LEU.2015.261
P577
2015-09-29T00:00:00Z
P6179
1053169650